The Psilocybin Patent Race Is On

Earlier this week, NeonMind (NMDBF) filed for four provisional patents. Psilocybin Alpha said, “The provisional patent applications include data derived from NeonMind’s initial preclinical trial that began in November 2020, which examined the potential use of psilocybin as a treatment for weight loss. NeonMind’s proprietary preclinical data shows promise that both low and high dose psilocybin may reduce weight gain and that the reduction in weight gain can occur in a short period of time.” The company recently appointed pharmaceutical executive Robert Tessarolo as its President and CEO.